Brokerages Expect aTyr Pharma, Inc. (LIFE) to Announce -$0.35 Earnings Per Share

Equities research analysts expect that aTyr Pharma, Inc. (NASDAQ:LIFE) will report earnings per share of ($0.35) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for aTyr Pharma’s earnings, with the lowest EPS estimate coming in at ($0.38) and the highest estimate coming in at ($0.32). aTyr Pharma reported earnings of ($0.56) per share in the same quarter last year, which suggests a positive year over year growth rate of 37.5%. The business is scheduled to announce its next quarterly earnings report on Thursday, May 10th.

According to Zacks, analysts expect that aTyr Pharma will report full year earnings of ($1.40) per share for the current financial year, with EPS estimates ranging from ($1.73) to ($1.03). For the next financial year, analysts expect that the company will post earnings of ($1.62) per share, with EPS estimates ranging from ($2.25) to ($1.03). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that cover aTyr Pharma.

How to Become a New Pot Stock Millionaire

aTyr Pharma (NASDAQ:LIFE) last released its earnings results on Monday, March 19th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.04.

A number of research firms have recently issued reports on LIFE. Zacks Investment Research raised shares of aTyr Pharma from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a report on Tuesday, April 3rd. JPMorgan Chase cut shares of aTyr Pharma from a “neutral” rating to an “underweight” rating in a research report on Wednesday, February 14th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $4.67.

Several hedge funds have recently made changes to their positions in LIFE. Deutsche Bank AG acquired a new stake in shares of aTyr Pharma in the fourth quarter valued at approximately $199,000. Dimensional Fund Advisors LP increased its position in shares of aTyr Pharma by 44.1% in the third quarter. Dimensional Fund Advisors LP now owns 83,848 shares of the biotechnology company’s stock valued at $423,000 after buying an additional 25,676 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of aTyr Pharma by 143.2% in the fourth quarter. Renaissance Technologies LLC now owns 279,400 shares of the biotechnology company’s stock valued at $978,000 after buying an additional 164,500 shares in the last quarter. Finally, Artal Group S.A. increased its position in shares of aTyr Pharma by 100.0% in the fourth quarter. Artal Group S.A. now owns 500,000 shares of the biotechnology company’s stock valued at $1,750,000 after buying an additional 250,000 shares in the last quarter. 58.90% of the stock is currently owned by hedge funds and other institutional investors.

Shares of aTyr Pharma stock traded up $0.02 during trading hours on Thursday, reaching $2.37. 779 shares of the company’s stock were exchanged, compared to its average volume of 43,548. aTyr Pharma has a 1 year low of $2.30 and a 1 year high of $6.50. The company has a quick ratio of 8.37, a current ratio of 8.37 and a debt-to-equity ratio of 0.23.

TRADEMARK VIOLATION WARNING: This piece was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at

About aTyr Pharma

aTyr Pharma, Inc, a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings.

Get a free copy of the Zacks research report on aTyr Pharma (LIFE)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for aTyr Pharma (NASDAQ:LIFE)

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with's FREE daily email newsletter.

Leave a Reply